Nitroglicerina Doc Generici (Glyceryl Trinitrate)

Glyceryl trinitrate is converted in the body to nitric oxide, which activates guanylate cyclase in vascular smooth muscle. The resulting rise in cyclic GMP causes relaxation of veins and arteries, lowering preload and afterload, and improving coronary blood flow to relieve myocardial ischemia.

The exact dose and patch‑changing schedule are determined by the prescribing clinician based on the patient’s condition, response, and tolerance. Dosage may be individualized, and patients should follow the prescriber’s instructions without self‑adjusting the regimen.

The pregnancy category for glyceryl trinitrate is listed as unknown. It should only be used during pregnancy or lactation if the potential benefit justifies the potential risk to the fetus or infant, and only under direct medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with oral nitrates, the transdermal patch provides more stable plasma levels and reduces the frequency of dosing. Unlike beta‑blockers, it does not affect heart rate directly but primarily lowers preload. It is often used when patients need rapid symptom control or cannot tolerate oral agents.

Store the patch at room temperature below 25 °C. Keep it in the original packaging, protect it from moisture, heat, and direct sunlight. Do not freeze or expose the product to extreme temperatures, as this may affect its adhesive properties and drug content.

The medication is applied as a transdermal patch to clean, dry, hair‑free skin, typically on the chest, upper arm, or back. The patch should be pressed firmly for several seconds, and the site should be rotated with each new application to minimize skin irritation.

The most critical risks include severe hypotension, syncope (fainting), methemoglobinemia, and rare but life‑threatening allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience sudden dizziness, fainting, or signs of an allergic response.

Individuals with known hypersensitivity to glyceryl trinitrate or any component of the patch should avoid it. It is also contraindicated in patients currently taking phosphodiesterase‑5 inhibitors, those with severe anemia, or anyone with markedly low blood pressure unless specifically directed by a physician.